NL-OMON46189
Completed
Phase 3
A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- CF
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 14
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria: a) A documented sweat chloride \* 60 mEq/L by quantitative pilocarpineiontophoresis (QPIT) b) A documented genotype with two disease\-causing mutations in the CFTR gene ;Informed consent by parent or legal guardian;Age \* 36 months and \*72 months at Screening visit ;Ability to comply with medication use, study visits and study procedures as judged by the site investigator;\*\*\*Ability to execute a technician controlled or spirometer controlled chest CT scan\*\*\*????
Exclusion Criteria
- •Chest CT within 8 months prior to the Screening visit;Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding Screening or Enrolment visit;Acute wheezing at Screening or Enrollment visit ;Oxygen saturation \< 95% (\<90% at centres above 4000 feet elevation) at Screening or Enrollment visit ;Other major organ dysfunction, excluding pancreatic dysfunction;Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator;Investigational drug use within 30 days prior to Screening or Enrolment visit;Treatment with inhaled hypertonic saline at any concentration within 30 days prior to Screening or Enrolment visit;Start of any additional inhaled saline solution at any concentration, or other hydrating agent such as mannitol or mucolytic drug such as dornase alpha within 30 days prior or following the Screening or Enrollment visit;Chronic lung disease not related to CF ;Inability to tolerate first dose of study treatment at the Enrolment visit
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infantsNL-OMON49743Pfizer14
Completed
Phase 3
A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatmentdiabetesDiabetes mellitus type 210018424NL-OMON38357Boehringer Ingelheim18
Completed
Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral SclerosisNL-OMON48938Orphazyme A/S19
Completed
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist TherapyCrohn's Disease10017969NL-OMON38117Janssen-Cilag32
Completed
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Studychronic migraineheadache10019231NL-OMON46093Eli Lilly54